Zacks: Analysts Anticipate Chemomab Therapeutics Ltd. (NASDAQ:CMMB) to Announce -$0.02 Earnings Per Share

Equities analysts expect Chemomab Therapeutics Ltd. (NASDAQ:CMMB) to post ($0.02) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Chemomab Therapeutics’ earnings. Chemomab Therapeutics posted earnings per share of ($5.60) during the same quarter last year, which suggests a positive year-over-year growth rate of 99.6%. The company is expected to announce its next quarterly earnings report on Monday, November 15th.

On average, analysts expect that Chemomab Therapeutics will report full year earnings of ($0.04) per share for the current financial year, with EPS estimates ranging from ($0.06) to ($0.01). For the next year, analysts forecast that the company will report earnings of ($0.08) per share, with EPS estimates ranging from ($0.08) to ($0.07). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that follow Chemomab Therapeutics.

Chemomab Therapeutics (NASDAQ:CMMB) last announced its quarterly earnings data on Thursday, August 12th. The company reported ($0.26) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.27) by $0.01.

Several research firms have recently commented on CMMB. Zacks Investment Research lowered shares of Chemomab Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, September 2nd. Oppenheimer began coverage on shares of Chemomab Therapeutics in a report on Friday, July 2nd. They issued a “buy” rating and a $42.00 price target for the company.

Several hedge funds have recently added to or reduced their stakes in the business. Orbimed Advisors LLC bought a new stake in shares of Chemomab Therapeutics during the 1st quarter worth about $74,019,000. Ikarian Capital LLC bought a new stake in shares of Chemomab Therapeutics in the 2nd quarter worth approximately $5,526,000. Marshall Wace LLP bought a new stake in shares of Chemomab Therapeutics in the 2nd quarter worth approximately $1,208,000. Marshall Wace North America L.P. bought a new stake in shares of Chemomab Therapeutics in the 2nd quarter worth approximately $837,000. Finally, Meitav Dash Investments Ltd. raised its holdings in shares of Chemomab Therapeutics by 389.3% in the 2nd quarter. Meitav Dash Investments Ltd. now owns 40,664 shares of the company’s stock worth $773,000 after purchasing an additional 32,353 shares in the last quarter. Institutional investors own 26.98% of the company’s stock.

Shares of NASDAQ CMMB traded down $0.24 during midday trading on Friday, hitting $12.04. The company’s stock had a trading volume of 31,570 shares, compared to its average volume of 126,575. Chemomab Therapeutics has a 1-year low of $11.30 and a 1-year high of $168.80. The business has a fifty day simple moving average of $14.80. The firm has a market cap of $137.26 million, a price-to-earnings ratio of -1.19 and a beta of 0.82.

About Chemomab Therapeutics

Chemomab Therapeutics Ltd. engages in the research and development of biological drugs for the treatment of inflammatory and fibrotic diseases. The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 16, 2021. Chemomab Therapeutics Ltd.

Featured Article: How Short Selling Works

Get a free copy of the Zacks research report on Chemomab Therapeutics (CMMB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Chemomab Therapeutics (NASDAQ:CMMB)

Receive News & Ratings for Chemomab Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemomab Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.